Labelling of Re-ABP with 188Re for bone pain palliation

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Chemistry
• Oncology

Background:

• Bisphosphonates like etidronate and medronate are used in bone imaging and pain palliation.
• Rhenium-188 (188Re) labeled compounds have shown efficacy in palliating pain from bone metastases.

Purpose of the Study:

• To develop and characterize a new radiopharmaceutical using alendronate (ABP) labeled with tin(II) fluoride-reduced rhenium-188 ([188Re]Re-ABP).
• To evaluate [188Re]Re-ABP as a potential agent for bone metastases pain palliation.

Main Methods:

• Alendronate (ABP) was labeled with SnF2-reduced 188Re using KReO4 and gentisic acid in an acidic medium.
• Chemical, spectroscopic, and microscopic characteristics were analyzed.
• Quality control and rat bone uptake studies were performed.

Main Results:

• The labeling of alendronate with 188Re was successfully achieved.
• Characterization confirmed the chemical and physical properties of the new radiopharmaceutical.
• Rat bone uptake studies demonstrated the potential of [188Re]Re-ABP for bone targeting.

Conclusions:

• The developed [188Re]Re-ABP is a promising new radiopharmaceutical.
• It shows potential for the palliation of pain associated with bone metastases.